Turner, Nicholas A.
Zaharoff, Smitha
King, Heather
Evans, Scott
Hamasaki, Toshimitsu
Lodise, Thomas
Ghazaryan, Varduhi
Beresnev, Tatiana
Riccobene, Todd
Patel, Rinal
Doernberg, Sarah B.
Rappo, Urania
Fowler, Vance G. Jr
Holland, Thomas L. http://orcid.org/0000-0001-7745-9010
,
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (UM1AI104681)
Article History
Received: 17 February 2022
Accepted: 28 April 2022
First Online: 16 May 2022
Declarations
:
: This study utilizes a centralized institutional review board (IRB) through WCG. The study protocol and centralized IRB conclusion will be reviewed and adopted by each site’s relevant local IRB prior to participation. All subjects require written informed consent to participate.
: Consent for publication was sought and approved by all listed authors, study sponsor (NIH/ARLG), and Abbvie (which provided study drug). Model informed consent form available upon request.
: The authors report no competing interests with the work submitted. For full disclosure, the authors report the following outside financial activities: Vance G. Fowler reports receiving consultancy fees from Novartis, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., MedImmune, Bayer, Basilea, Affinergy, Janssen, Contrafect, Regeneron, Destiny, Amphliphi Biosciences, Integrated Biotherapeutics, C3J, Armata, Valanbio, Akagera, Aridis, and Roche; grants from NIH, MedImmune, Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Merck, Medical Biosurfaces, Locus, Affinergy, Contrafect, Karius, Genentech, Regeneron, Basilea, and Janssen; royalties from UptoDate; stock options in Valanbio and ArcBio; and an editorial stipend from the Infectious Diseases Society of America. Thomas L. Holland reports serving on the scientific advisory board for Motif Bio, consulting for Basilea, Motif Bio, Genentech, and Theravance. Heather King reports receiving consultancy feeds from Merck.